Kisspeptin-10
Kisspeptin-10 is a peptide, indexed here under Endocrine and immune signalling peptides.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Endocrine and immune signalling peptides |
| CAS registry number | 374675-21-5[1] |
| PubChem CID | 25240297[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C63H83N17O14[1] |
| Molecular weight | 1302.4 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Kisspeptin-10 is described in the retrieved literature as a decapeptide derived from KiSS-1, also reported as metastin. A 2004 Journal of Cell Science paper characterises it in those terms, and a 2004 Journal of Neuroendocrinology paper reports that central and peripheral administration stimulates the hypothalamic-pituitary-gonadal axis.
The retrieved set is largely reproductive endocrinology. Two 2011 papers in the Journal of Clinical Endocrinology and Metabolism report it as a potent stimulator of luteinising hormone that increases pulse frequency, and that its effects on reproductive hormone release show sexual dimorphism. A 2009 Endocrinology paper reports facilitation of a plasma membrane-driven calcium oscillator, and a 2009 Cancer Research paper reports inhibition of tumour angiogenesis.
[3, 4, 5, 6, 7, 8]Reported mechanism
A KiSS-1 derived decapeptide reported in the retrieved records to stimulate the hypothalamic-pituitary-gonadal axis and luteinising hormone release.
[4, 5]Stated in the titles of the cited 2004 Journal of Neuroendocrinology and 2011 Journal of Clinical Endocrinology and Metabolism papers.
Targets named in the cited records: kisspeptin receptor, luteinising hormone release.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Kisspeptin-10 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- metastin 45-54
- KiSS-1 derived decapeptide
- kisspeptin
Where this page sits
Research records
Cited research records for Kisspeptin-10, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Gonadorelin — Endocrine and immune signalling peptides
- Delta sleep-inducing peptide — Endocrine and immune signalling peptides
- Oxytocin — Endocrine and immune signalling peptides
- Thymosin alpha 1 — Endocrine and immune signalling peptides
Class page: Endocrine and immune signalling peptides. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Kisspeptin-10?
Kisspeptin-10 is described in the retrieved literature as a decapeptide derived from KiSS-1, also reported as metastin. A 2004 Journal of Cell Science paper characterises it in those terms, and a 2004 Journal of Neuroendocrinology paper reports that central and peripheral administration stimulates the hypothalamic-pituitary-gonadal axis.
Which class is Kisspeptin-10 indexed under?
Kisspeptin-10 is indexed under Endocrine and immune signalling peptides. This class groups peptides whose retrieved literature concerns endocrine or immune signalling outside the growth hormone axis.
What does the FDA application register show for Kisspeptin-10?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 25240297, Kisspeptin-10. PubChem, National Library of Medicine (2026). pubchem:25240297
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:kisspeptin-10
- Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. Journal of cell science (2004). pmid:15020672
- Central and peripheral administration of kisspeptin-10 stimulates the hypothalamic-pituitary-gonadal axis. Journal of neuroendocrinology (2004). pmid:15500545
- Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. The Journal of clinical endocrinology and metabolism (2011). pmid:21632807
- The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. The Journal of clinical endocrinology and metabolism (2011). pmid:21976724
- Kisspeptin-10 facilitates a plasma membrane-driven calcium oscillator in gonadotropin-releasing hormone-1 neurons. Endocrinology (2009). pmid:18948403
- Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer research (2009). pmid:19671799
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.